The Latest Cardiac and Vascular News
First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022 First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022 First quarter 2023 EYLEA® U.S. net sales were $1.43 billion First quarter […]
Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other […]
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally […]
Regeneron’s press release reporting its second quarter 2022 results is also available on its media and investor relations website (http://newsroom.regeneron.com) Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 20% Second quarter 2022 EYLEA® U.S. […]
TARRYTOWN, N.Y., Feb. 4, 2022 /PRNewswire/ — Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV®(2); revenues excluding REGEN-COV(1) increased 17% Full year 2021 revenues increased 89% to $16.07 billion compared to full year 2020 including $6.19 billion attributable to REGEN-COV(2); revenues excluding REGEN-COV(1) increased […]
Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. […]
TARRYTOWN, N.Y., Oct. 29, 2020 /PRNewswire/ — Regeneron has been consistently ranked #1 or 2 Top Employer for past 10 years Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as the top company to work for by Science magazine […]
TARRYTOWN, N.Y., Aug. 12, 2020 /PRNewswire/ — Homozygous familial hypercholesterolemia affects approximately 1,300 patients in the U.S., the vast majority of whom are unable to reach target LDL-C levels with currently available therapies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food […]
TARRYTOWN, N.Y., July 8, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020, before the U.S. financial markets open. The Company will host a conference call and simultaneous […]
TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ — Results from separate positive Phase 3 trial of Praluent® (alirocumab) in patients with HoFH also presented; FDA regulatory submission planned for Q2 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase 3 results of evinacumab were presented […]
